NIP292

Status
Phase 1
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

NIP292 is a new small-molecule drug with multiple mechanisms such as anti-inflammatory, anti-fibrosis, expansion of blood vessels, and repair of vascular endothelial damage. 

Study Purpose

This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >